TDO2 and metabolic dysfunction-associated steatotic liver disease: Recently, Qin and Zhou [38] found that knockdown of TDO2 in NAFLD mice inhibited hepatic lipid deposition and hepatic fibrosis and reduced the expression of markers related to hepatic lipid deposition and fibrosis in PA-treated primary hepatocytes by inactivating the NF-κB pathway.